

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 October 2024 (10.10.2024)



(10) International Publication Number
WO 2024/211343 A1

(51) International Patent Classification:

A61K 31/17 (2006.01) C07D 405/14 (2006.01)
A61K 31/16 (2006.01) C07D 413/14 (2006.01)
A61K 31/44 (2006.01) C07D 241/02 (2006.01)
A61K 31/496 (2006.01) A61P 5/00 (2006.01)
C07D 241/04 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(21) International Application Number:

PCT/US2024/022738

Published:

- with international search report (Art. 21(3))

(22) International Filing Date:

03 April 2024 (03.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/457,144 05 April 2023 (05.04.2023) US

(71) Applicant: **CRINETICS PHARMACEUTICALS, INC.**
[US/US]; 6055 Lusk Blvd., San Diego, California 92121
(US).

(72) Inventors: **TRAINER, Peter**; c/o Crinetics Pharmaceuti-
cals, Inc., 6055 Lusk Blvd., San Diego, California 92121
(US). **KRASNER, Alan S.**; c/o Crinetics Pharmaceuticals
Inc., 6055 Lusk Blvd., San Diego, California 92121 (US).
LUO, Sha; c/o Crinetics Pharmaceuticals, Inc., 6055 Lusk
Blvd., San Diego, California 92121 (US).

(74) Agent: **CAPPS, Kevin** et al.; Crinetics Pharmaceuticals,
Inc., Legal IP, 6055 Lusk Blvd., San Diego, California
92121 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONIST FOR THE TREATMENT OF ACTH-DEPEN-
DENT CUSHING'S SYNDROME

(57) Abstract: Provided herein are methods and compositions for the treatment of ACTH-dependent Cushing's syndrome.

WO 2024/211343 A1